vs
Guardant Health, Inc.（GH）与STURM RUGER & CO INC（RGR）财务数据对比。点击上方公司名可切换其他公司
Guardant Health, Inc.的季度营收约是STURM RUGER & CO INC的1.9倍（$281.3M vs $151.1M），Guardant Health, Inc.同比增速更快（39.4% vs 3.6%），STURM RUGER & CO INC自由现金流更多（$12.3M vs $-54.2M），过去两年Guardant Health, Inc.的营收复合增速更高（29.2% vs 5.1%）
Guardant Health, Inc.是总部位于美国加利福尼亚州帕洛阿尔托的生物技术企业，由Helmy Eltoukhy与AmirAli Talasaz联合创立，目前二人共同出任公司首席执行官，统筹公司战略规划与日常运营管理工作。
鲁格公司（Ruger）是总部位于美国康涅狄格州绍斯波特的枪械制造企业，除总部外，还在新罕布什尔州纽波特、北卡罗来纳州梅约丹以及亚利桑那州普雷斯科特设有生产工厂。公司由亚历山大·麦考密克·斯特姆与威廉·B·鲁格于1949年共同创立，自1969年起公开上市交易。
GH vs RGR — 直观对比
营收规模更大
GH
是对方的1.9倍
$151.1M
营收增速更快
GH
高出35.7%
3.6%
自由现金流更多
RGR
多$66.6M
$-54.2M
两年增速更快
GH
近两年复合增速
5.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $281.3M | $151.1M |
| 净利润 | $-128.5M | — |
| 毛利率 | 64.6% | 17.8% |
| 营业利润率 | -43.0% | 2.3% |
| 净利率 | -45.7% | — |
| 营收同比 | 39.4% | 3.6% |
| 净利润同比 | -15.8% | — |
| 每股收益（稀释后） | $-1.01 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GHRGR
| Q4 25 | $281.3M | $151.1M | ||
| Q3 25 | $265.2M | $126.8M | ||
| Q2 25 | $232.1M | $132.5M | ||
| Q1 25 | $203.5M | $135.7M | ||
| Q4 24 | $201.8M | $145.8M | ||
| Q3 24 | $191.5M | $122.3M | ||
| Q2 24 | $177.2M | $130.8M | ||
| Q1 24 | $168.5M | $136.8M |
净利润GHRGR
| Q4 25 | $-128.5M | — | ||
| Q3 25 | $-92.7M | $1.6M | ||
| Q2 25 | $-99.9M | $-17.2M | ||
| Q1 25 | $-95.2M | $7.8M | ||
| Q4 24 | $-111.0M | — | ||
| Q3 24 | $-107.8M | $4.7M | ||
| Q2 24 | $-102.6M | $8.3M | ||
| Q1 24 | $-115.0M | $7.1M |
毛利率GHRGR
| Q4 25 | 64.6% | 17.8% | ||
| Q3 25 | 64.7% | 15.1% | ||
| Q2 25 | 65.0% | 3.9% | ||
| Q1 25 | 63.3% | 22.0% | ||
| Q4 24 | 61.6% | 22.8% | ||
| Q3 24 | 61.1% | 18.5% | ||
| Q2 24 | 59.1% | 22.3% | ||
| Q1 24 | 61.2% | 21.5% |
营业利润率GHRGR
| Q4 25 | -43.0% | 2.3% | ||
| Q3 25 | -37.3% | -2.7% | ||
| Q2 25 | -45.9% | -15.6% | ||
| Q1 25 | -54.6% | 6.2% | ||
| Q4 24 | -62.4% | 7.8% | ||
| Q3 24 | -61.3% | 3.1% | ||
| Q2 24 | -56.8% | 6.9% | ||
| Q1 24 | -59.2% | 5.5% |
净利率GHRGR
| Q4 25 | -45.7% | — | ||
| Q3 25 | -35.0% | 1.2% | ||
| Q2 25 | -43.0% | -13.0% | ||
| Q1 25 | -46.8% | 5.7% | ||
| Q4 24 | -55.0% | — | ||
| Q3 24 | -56.3% | 3.9% | ||
| Q2 24 | -57.9% | 6.3% | ||
| Q1 24 | -68.2% | 5.2% |
每股收益（稀释后）GHRGR
| Q4 25 | $-1.01 | $0.22 | ||
| Q3 25 | $-0.74 | $0.10 | ||
| Q2 25 | $-0.80 | $-1.05 | ||
| Q1 25 | $-0.77 | $0.46 | ||
| Q4 24 | $-0.90 | $0.62 | ||
| Q3 24 | $-0.88 | $0.28 | ||
| Q2 24 | $-0.84 | $0.47 | ||
| Q1 24 | $-0.94 | $0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $378.2M | $92.5M |
| 总债务越低越好 | $1.5B | — |
| 股东权益账面价值 | $-99.3M | $283.8M |
| 总资产 | $2.0B | $342.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GHRGR
| Q4 25 | $378.2M | $92.5M | ||
| Q3 25 | $580.0M | $80.8M | ||
| Q2 25 | $629.1M | $101.4M | ||
| Q1 25 | $698.6M | $108.3M | ||
| Q4 24 | $525.5M | $105.5M | ||
| Q3 24 | $585.0M | $96.0M | ||
| Q2 24 | $933.7M | $105.6M | ||
| Q1 24 | $1.0B | $115.3M |
总债务GHRGR
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益GHRGR
| Q4 25 | $-99.3M | $283.8M | ||
| Q3 25 | $-354.5M | $279.6M | ||
| Q2 25 | $-305.5M | $289.3M | ||
| Q1 25 | $-250.8M | $321.5M | ||
| Q4 24 | $-139.6M | $319.6M | ||
| Q3 24 | $-60.1M | $314.9M | ||
| Q2 24 | $-1.6M | $321.5M | ||
| Q1 24 | $68.3M | $332.0M |
总资产GHRGR
| Q4 25 | $2.0B | $342.0M | ||
| Q3 25 | $1.3B | $342.3M | ||
| Q2 25 | $1.3B | $349.5M | ||
| Q1 25 | $1.3B | $379.0M | ||
| Q4 24 | $1.5B | $384.0M | ||
| Q3 24 | $1.5B | $373.5M | ||
| Q2 24 | $1.6B | $376.7M | ||
| Q1 24 | $1.7B | $385.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-26.4M | $15.5M |
| 自由现金流经营现金流 - 资本支出 | $-54.2M | $12.3M |
| 自由现金流率自由现金流/营收 | -19.3% | 8.2% |
| 资本支出强度资本支出/营收 | 9.9% | 2.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-233.1M | $38.5M |
8季度趋势，按日历期对齐
经营现金流GHRGR
| Q4 25 | $-26.4M | $15.5M | ||
| Q3 25 | $-35.4M | $12.9M | ||
| Q2 25 | $-60.3M | $14.7M | ||
| Q1 25 | $-62.7M | $11.1M | ||
| Q4 24 | $-64.5M | $20.0M | ||
| Q3 24 | $-51.1M | $9.4M | ||
| Q2 24 | $-94.0M | $18.7M | ||
| Q1 24 | $-30.3M | $7.3M |
自由现金流GHRGR
| Q4 25 | $-54.2M | $12.3M | ||
| Q3 25 | $-45.8M | $7.0M | ||
| Q2 25 | $-65.9M | $9.1M | ||
| Q1 25 | $-67.1M | $10.0M | ||
| Q4 24 | $-83.4M | $16.4M | ||
| Q3 24 | $-55.3M | $2.6M | ||
| Q2 24 | $-99.1M | $10.1M | ||
| Q1 24 | $-37.2M | $5.6M |
自由现金流率GHRGR
| Q4 25 | -19.3% | 8.2% | ||
| Q3 25 | -17.3% | 5.5% | ||
| Q2 25 | -28.4% | 6.9% | ||
| Q1 25 | -33.0% | 7.4% | ||
| Q4 24 | -41.3% | 11.2% | ||
| Q3 24 | -28.9% | 2.1% | ||
| Q2 24 | -55.9% | 7.7% | ||
| Q1 24 | -22.1% | 4.1% |
资本支出强度GHRGR
| Q4 25 | 9.9% | 2.1% | ||
| Q3 25 | 3.9% | 4.6% | ||
| Q2 25 | 2.4% | 4.2% | ||
| Q1 25 | 2.2% | 0.8% | ||
| Q4 24 | 9.4% | 2.5% | ||
| Q3 24 | 2.2% | 5.5% | ||
| Q2 24 | 2.9% | 6.6% | ||
| Q1 24 | 4.1% | 1.3% |
现金转化率GHRGR
| Q4 25 | — | — | ||
| Q3 25 | — | 8.15× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.43× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 2.27× | ||
| Q1 24 | — | 1.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
